Foreign Drug Presence Gaining Across China's Primary Healthcare Market
This article was originally published in PharmAsia News
Executive Summary
The extensive inclusion of foreign brand drugs in Shanghai's 2010 provincial essential drug list and China's upcoming price-cuts on brand drugs have sparked industry concerns that foreign branded drugs will further dominate the country's drug market by entering its primary healthcare segment
|
The extensive inclusion of foreign brand drugs in Shanghai's 2010 provincial essential drug list and China's upcoming price-cuts on brand drugs have sparked industry concerns that foreign branded drugs will further dominate the country's drug market by entering its primary healthcare segment. A SINO-PhIRDA report indicated that foreign brand drugs account for 65 to 80 percent of prescription sales in China's Class 3A hospitals and are increasing their market presence. According to one newspaper's statistics, 27 percent of Shanghai's additional essential chemical drugs are produced by foreign drug makers or their Chinese joint ventures. (Click Here For More - Chinese Language) "High-Profit Foreign Drug Makers Enter Shanghai's Additional Essential Drug List; Shanghai Takes All Foreign Drug Winners" - health.sohu.com (12/15/2010) |